Works matching IS 11738804 AND DT 2019 AND VI 33 AND IP 1

Results: 12

FKB327: An Adalimumab Biosimilar.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 113, doi. 10.1007/s40259-019-00335-8

By:

Al-Salama, Zaina T.

Publication type:

Article

Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 117, doi. 10.1007/s40259-019-00334-9

By:

Hoy, Sheridan M.

Publication type:

Article

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 15, doi. 10.1007/s40259-019-00333-w

By:

T. Virtanen, Anniina;
Haikarainen, Teemu;
Raivola, Juuli;
Silvennoinen, Olli

Publication type:

Article

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 79, doi. 10.1007/s40259-018-00331-4

By:

Suh, Chang-Hee;
Yoo, Dae Hyun;
Berrocal Kasay, Alfredo;
Chalouhi El-Khouri, Elia;
Cons Molina, Francisco Fidenci;
Shesternya, Pavel;
Miranda, Pedro;
Medina-Rodriguez, Francisco G.;
Wiland, Piotr;
Jeka, Slawomir;
Chavez-Corrales, Jose;
Linde, Thomas;
Hrycaj, Pawel;
Abello-Banfi, Mauricio;
Hospodarskyy, Ihor;
Jaworski, Janusz;
Piotrowski, Mariusz;
Brzosko, Marek;
Krogulec, Marek;
Shevchuk, Sergii

Publication type:

Article

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 121, doi. 10.1007/s40259-018-0330-1

By:

Niazi, Sarfaraz K.

Publication type:

Article

Current Ebola Virus Vaccine Progress.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 9, doi. 10.1007/s40259-018-0329-7

By:

Marzi, Andrea;
Mire, Chad E.

Publication type:

Article

The Impact of the Fecal Microbiome on Cancer Immunotherapy.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 1, doi. 10.1007/s40259-018-0328-8

By:

Osman, Afaf E. G.;
Luke, Jason J.

Publication type:

Article

Monoclonal Antibodies for Multiple Sclerosis: An Update.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 61, doi. 10.1007/s40259-018-0327-9

By:

Graf, Jonas;
Aktas, Orhan;
Rejdak, Konrad;
Hartung, Hans-Peter

Publication type:

Article

A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 93, doi. 10.1007/s40259-018-0326-x

By:

Zhang, Tan;
Chen, Guihong;
Liu, Chang;
Zu, Li'an;
Wang, Qi;
Wang, Yitong;
Lv, Jie;
An, Youzhong;
Dong, Lihou;
Cheng, Huiyang;
Ren, Shengbin;
Wang, Qian;
Zheng, Qingshan;
Song, Haifeng;
Fang, Yi

Publication type:

Article

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 33, doi. 10.1007/s40259-018-0325-y

By:

Busse, Paula J.;
Farkas, Henriette;
Banerji, Aleena;
Lumry, William R.;
Longhurst, Hilary J.;
Sexton, Daniel J.;
Riedl, Marc A.

Publication type:

Article

Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 45, doi. 10.1007/s40259-018-0324-z

By:

Dholaria, Bhagirathbhai R.;
Bachmeier, Christina A.;
Locke, Frederick

Publication type:

Article

Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.

Published in:

BioDrugs, 2019, v. 33, n. 1, p. 101, doi. 10.1007/s40259-018-0323-0

By:

Kim, Seokuee;
Hong, Taegon;
Ko, Jae-Wook;
Huh, Wooseong;
Kim, Jung-Ryul

Publication type:

Article